Tirzepatide
Tirzepatide injection
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown remarkable efficacy in clinical trials, with participants achieving an average weight loss of up to 22.5% of body weight. It works through a novel dual-action mechanism targeting two key metabolic hormones.
Available Dosages
A licensed physician will review your health profile and determine if this medication is appropriate for you.
Medical Information
How It Works
Tirzepatide is administered as a once-weekly subcutaneous injection. It is the first dual GIP and GLP-1 receptor agonist, targeting two incretin hormones involved in blood sugar regulation and appetite control. Dosing starts low and is titrated upward every 4 weeks.
Potential Side Effects
The most common side effects include:
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Dyspepsia
- Abdominal pain
- Injection site reactions
Side effects are typically mild and tend to improve as your body adjusts to the medication. Contact your healthcare provider if you experience severe or persistent side effects.